Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 20/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5193340 | 0.91 | NOS2 (0.59) | NOS2 | |
| SCHEMBL5192625 | 0.91 | NOS2 (0.54) | NOS2 | |
| SCHEMBL5192137 | 0.90 | CTSL (0.43) | NOS2 | |
| SCHEMBL5192755 | 0.89 | NOS2 (0.54) | NOS2 | |
| SCHEMBL5192660 | 0.88 | NOS2 (0.51) | NOS2 | |
| SCHEMBL5194412 | 0.87 | NOS2 (0.56) | NOS2 | |
| SCHEMBL6306062 | 0.87 | NOS2 (0.52) | NOS2 | |
| SCHEMBL7245381 | 0.87 | NOS2 (0.47) | NOS2 | |
| SCHEMBL5192754 | 0.86 | NOS2 (0.51) | NOS2 | |
| SCHEMBL5192344 | 0.85 | NOS2 (0.53) | NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092678-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092678-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.